S225: CIRCULATING TUMOR DNA IS A PROGNOSTIC BIOMARKER AT BASELINE AND IMPROVES THE ACCURACY OF INTERIM PET IN CLASSIC HODGKIN LYMPHOMA. (23rd June 2022)